The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal
Open accessAbstract
Although several chemical structural classes of synthetic cannabinoids (SCs) were recently classified as Schedule I substances, rates of use and cases of serious toxic effects remain high. While case reports and media bring attention to severe SC toxicity, daily SC use resulting in dependence and withdrawal is a significant concern that is often overlooked when discussing the risks of these drugs. There is a rich literature on evidence-based approaches to treating substance use disorders associated with most abused drugs, yet little has been published regarding how to best treat symptoms related to SC dependence given its recency as an emerging clinically significant issue. This review provides a background of the pharmacology of SCs, recent findings of adverse effects associated with both acute intoxication and withdrawal as a consequence of daily use, and treatment approaches that have been implemented to address these issues, with an emphasis on pharmacotherapies for managing detoxification. In order to determine prevalence of use in cannabis smokers, a population at high risk for SC use, we obtained data on demographics of SC users, frequency of use, and adverse effects over a 3.5-year period (2012–2015) in the New York City metropolitan area, a region with a recent history of high SC use. While controlled studies on the physiological and behavioral effects of SCs are lacking, it is clear that risks associated with using these drugs pertain not only to the unpredictable and severe nature of acute intoxication but also to the effects of long-term, chronic use. Recent reports in the literature parallel findings from our survey, indicating that there is a subset of people who use SCs daily. Although withdrawal has not been systematically characterized and effective treatments have yet to be elucidated, some symptom relief has been reported with benzodiazepines and the atypical antipsychotic, quetiapine. Given the continued use and abuse of SCs, empirical studies characterizing (1) SCs acute effects, (2) withdrawal upon cessation of use, and (3) effective treatment strategies for SC use disorder are urgently needed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications
Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R. L., Pirard, S., & Huestis, M. A. (2014) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2014.08.005 · Cited by 709
‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?
Auwärter, V., Dresen, S., Weinmann, W., Müller, M., Pütz, M., & Ferreirós, N. (2009) · Journal of Mass Spectrometry · doi:10.1002/jms.1558 · Cited by 660
Hermanns‐Clausen, M., Kneisel, S., Szabo, B., & Auwärter, V. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04078.x · Cited by 479
Beyond THC: The New Generation of Cannabinoid Designer Drugs
Fattore, L., & Fratta, W. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00060 · Cited by 443
Winstock, A. R., & Barratt, M. J. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.12.011 · Cited by 331
Internalization and Recycling of the CB1 Cannabinoid Receptor
Hsieh, C., Brown, S., Derleth, C., & Mackie, K. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0730493.x · Cited by 296
Spicing things up: synthetic cannabinoids
Spaderna, M., Addy, P. H., & D’Souza, D. C. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3188-4 · Cited by 296
A survey study to characterize use of Spice products (synthetic cannabinoids)
Vandrey, R., Dunn, K. E., Fry, J. A., & Girling, E. R. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2011.07.011 · Cited by 283
Withdrawal Phenomena and Dependence Syndrome After the Consumption of „Spice Gold“
Zimmermann, U. S., Winkelmann, P. R., Pilhatsch, M., Nees, J. A., Spanagel, R., & Schulz, K. (2009) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2009.0464 · Cited by 278
Delay of reinforcement: A historical review.
Renner, K. E. (1964) · Psychological Bulletin · doi:10.1037/h0048335 · Cited by 271
Cited by
Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex
Krishna Kumar, K., Shalev-Benami, M., Robertson, M. J., Hu, H., Banister, S. D., Hollingsworth, S. A., Latorraca, N. R., Kato, H. E., Hilger, D., Maeda, S., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.040 · Cited by 419
New psychoactive substances: a review and updates
Shafi, A., Berry, A. J., Sumnall, H., Wood, D. M., & Tracy, D. K. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320967197 · Cited by 347
The cannabis withdrawal syndrome: current insights
Bonnet, U., & Preuss, U. (2017) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s109576 · Cited by 221
Onaolapo, O. J., Olofinnade, A. T., Ojo, F. O., Adeleye, O., Falade, J., & Onaolapo, A. Y. (2022) · World Journal of Psychiatry · doi:10.5498/wjp.v12.i10.1268 · Cited by 61
Metadata
- Authors
- Cooper, Z. D.
- Venue
- Current Psychiatry Reports
- Published
- 2016-04-14
- Volume
- 18
- Issue
- 5
- Pages
- 52-52
- ISSN
- 1523-3812 (ISSN-L)
- 1535-1645
- OpenAlex
- W2337155940
- Cited by
- 253
- References
- 52
- FWCI
- 36.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. https://app.cochat.ai/papers/10.1007/s11920-016-0694-1
- The paper
- Cooper, Z. D. (2016). Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal. Current Psychiatry Reports. https://doi.org/10.1007/s11920-016-0694-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.